Skip to main content
. 2016 Jul 20;7(35):56713–56725. doi: 10.18632/oncotarget.10723
CAT forward: 5′---TTTCCCAGGAAGATCCTGAC---3′
reverse: 5′---ACCTTGGTGAGATCGAATGG---3′
CHOP forward: 5′---CATCACCACACCTGAAAGCA---3′
reverse: 5′---TCAGCTGCCATCTCTGCA---3′
GAPDH forward: 5′---CTCTCTGCTCCTCCTGTTCGAC---3′
reverse: 5′---TGAGCGATGTGGCTCGGCT---3′
GPX1 forward: 5′---TTCCCGTGCAACCAGTTTG---3′
reverse: 5′---TTCACCTCGCACTTCTCGAA---3′
GPX4 forward: 5′---TACGGACCCATGGAGGAG---3′
reverse: 5′---CCACACACTTGTGGAGCTAGAA---3′
PRX2 forward: 5′---CAGACGAGCATGGGGAAG---3′
reverse: 5′---ACGTTGGGCTTAATCGTGTC---3′
SOD1 forward: 5′---AGGGCATCATCAATTTCGAG---3′
reverse: 5′---TGCCTCTCTTCATCCTTTGG---3′
SOD2 forward: 5′---GGAAGCCATCAAACGTGACT---3′
reverse: 5′---CTGATTTGGACAAGCAGCAA---3′